Skip to main content
Top
Published in: Arthritis Research & Therapy 1/2015

Open Access 01-12-2015 | Research article

Anti-citrullinated protein antibodies contribute to platelet activation in rheumatoid arthritis

Authors: Kim L.L. Habets, Leendert A. Trouw, E.W. Nivine Levarht, Suzanne J.A. Korporaal, Petra A.M. Habets, Philip de Groot, Tom W.J. Huizinga, René E.M. Toes

Published in: Arthritis Research & Therapy | Issue 1/2015

Login to get access

Abstract

Introduction

Although the role of platelets in rheumatoid arthritis (RA) is relatively unexplored, recent studies point towards a contribution of platelets in arthritis. We set out to determine platelet phenotype in RA and studied whether this could be influenced by the presence of anti-citrullinated protein antibodies (ACPA).

Methods

Platelets from healthy controls were incubated in the presence of plasma of patients with RA or age- and sex-matched healthy controls and plasma from ACPAneg or ACPApos patients or in the presence of plate-bound ACPA. Characteristics of platelets isolated from patients with RA were correlated to disease activity.

Results

Platelets isolated from healthy controls displayed markers of platelet activation in the presence of plasma derived from RA patients, as determined by P-selectin expression, formation of aggregates and secretion of soluble CD40 ligand (sCD40L). Furthermore, levels of P-selectin expression and sCD40L release correlated with high ACPA titres. In accordance with these findings, enhanced platelet activation was observed after incubation with ACPApos plasma versus ACPAneg plasma. Pre-incubation of platelets with blocking antibodies directed against low-affinity immunoglobulin G receptor (FcγRIIa) completely inhibited the ACPA-mediated activation. In addition, expression of P-selectin measured as number of platelets correlated with Disease Activity Score in 44 joints, C-reactive protein level, ACPA status and ACPA level.

Conclusions

We show for the first time that ACPA can mediate an FcγRIIa-dependent activation of platelets. As ACPA can be detected several years before RA disease onset and activated platelets contribute to vascular permeability, these data implicate a possible role for ACPA-mediated activation of platelets in arthritis onset.
Appendix
Available only for authorised users
Literature
1.
go back to reference Gasparyan AY. Platelets in inflammation and thrombosis. Inflamm Allergy Drug Targets. 2010;9:319–21.PubMedCrossRef Gasparyan AY. Platelets in inflammation and thrombosis. Inflamm Allergy Drug Targets. 2010;9:319–21.PubMedCrossRef
2.
3.
4.
go back to reference Cloutier N, Paré A, Farndale RW, Schumacher HR, Nigrovic PA, Lacroix S, et al. Platelets can enhance vascular permeability. Blood. 2012;120:1334–43.PubMedCrossRef Cloutier N, Paré A, Farndale RW, Schumacher HR, Nigrovic PA, Lacroix S, et al. Platelets can enhance vascular permeability. Blood. 2012;120:1334–43.PubMedCrossRef
5.
go back to reference Huo Y, Ley KF. Role of platelets in the development of atherosclerosis. Trends Cardiovasc Med. 2004;14:18–22.PubMedCrossRef Huo Y, Ley KF. Role of platelets in the development of atherosclerosis. Trends Cardiovasc Med. 2004;14:18–22.PubMedCrossRef
6.
go back to reference Projahn D, Koenen RR. Platelets: key players in vascular inflammation. J Leukoc Biol. 2012;92:1167–75.PubMedCrossRef Projahn D, Koenen RR. Platelets: key players in vascular inflammation. J Leukoc Biol. 2012;92:1167–75.PubMedCrossRef
7.
go back to reference Henn V, Slupsky JR, Gräfe M, Anagnostopoulos I, Förster R, Müller-Berghaus G, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998;391:591–4.PubMedCrossRef Henn V, Slupsky JR, Gräfe M, Anagnostopoulos I, Förster R, Müller-Berghaus G, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998;391:591–4.PubMedCrossRef
8.
go back to reference Semple JW, Italiano Jr JE, Freedman J. Platelets and the immune continuum. Nat Rev Immunol. 2011;11:264–74.PubMedCrossRef Semple JW, Italiano Jr JE, Freedman J. Platelets and the immune continuum. Nat Rev Immunol. 2011;11:264–74.PubMedCrossRef
10.
go back to reference FitzGerald O, Soden M, Yanni G, Robinson R, Bresnihan B. Morphometric analysis of blood vessels in synovial membranes obtained from clinically affected and unaffected knee joints of patients with rheumatoid arthritis. Ann Rheum Dis. 1991;50:792–6.PubMedCrossRefPubMedCentral FitzGerald O, Soden M, Yanni G, Robinson R, Bresnihan B. Morphometric analysis of blood vessels in synovial membranes obtained from clinically affected and unaffected knee joints of patients with rheumatoid arthritis. Ann Rheum Dis. 1991;50:792–6.PubMedCrossRefPubMedCentral
11.
go back to reference Boilard E, Nigrovic PA, Larabee K, Watts GF, Coblyn JS, Weinblatt ME, et al. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science. 2010;327:580–3.PubMedCrossRefPubMedCentral Boilard E, Nigrovic PA, Larabee K, Watts GF, Coblyn JS, Weinblatt ME, et al. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science. 2010;327:580–3.PubMedCrossRefPubMedCentral
12.
13.
go back to reference Gasparyan AY, Ayvazyan L, Pretorius E, Kitas GD. Platelets in rheumatic diseases: friend or foe? Curr Pharm Des. 2014;20:552–66.PubMedCrossRef Gasparyan AY, Ayvazyan L, Pretorius E, Kitas GD. Platelets in rheumatic diseases: friend or foe? Curr Pharm Des. 2014;20:552–66.PubMedCrossRef
14.
go back to reference Knijff-Dutmer EA, Koerts J, Nieuwland R, Kalsbeek-Batenburg EM, van de Laar MA. Elevated levels of platelet microparticles are associated with disease activity in rheumatoid arthritis. Arthritis Rheum. 2002;46:1498–503.PubMedCrossRef Knijff-Dutmer EA, Koerts J, Nieuwland R, Kalsbeek-Batenburg EM, van de Laar MA. Elevated levels of platelet microparticles are associated with disease activity in rheumatoid arthritis. Arthritis Rheum. 2002;46:1498–503.PubMedCrossRef
15.
go back to reference Pamuk GE, Vural O, Turgut B, Demir M, Pamuk ON, Cakir N. Increased platelet activation markers in rheumatoid arthritis: are they related with subclinical atherosclerosis? Platelets. 2008;19:146–54.PubMedCrossRef Pamuk GE, Vural O, Turgut B, Demir M, Pamuk ON, Cakir N. Increased platelet activation markers in rheumatoid arthritis: are they related with subclinical atherosclerosis? Platelets. 2008;19:146–54.PubMedCrossRef
16.
go back to reference Cheng T, Li FF, Zhao S, Peng XC, Zhang XL. Soluble P selectin in synovial fluid level is correlated with the radiographic severity of knee osteoarthritis. Clin Chim Acta. 2010;411:1529–31.PubMedCrossRef Cheng T, Li FF, Zhao S, Peng XC, Zhang XL. Soluble P selectin in synovial fluid level is correlated with the radiographic severity of knee osteoarthritis. Clin Chim Acta. 2010;411:1529–31.PubMedCrossRef
17.
go back to reference Ertenli I, Kiraz S, Arici M, Haznedaroglu IC, Calgüneri M, Celik I, et al. P-selectin as a circulating molecular marker in rheumatoid arthritis with thrombocytosis. J Rheumatol. 1998;25:1054–8.PubMed Ertenli I, Kiraz S, Arici M, Haznedaroglu IC, Calgüneri M, Celik I, et al. P-selectin as a circulating molecular marker in rheumatoid arthritis with thrombocytosis. J Rheumatol. 1998;25:1054–8.PubMed
18.
go back to reference Prahalad S, Martins TB, Tebo AE, Whiting A, Clifford B, Zeft AS, et al. Elevated serum levels of soluble CD154 in children with juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2008;6:8.PubMedCrossRefPubMedCentral Prahalad S, Martins TB, Tebo AE, Whiting A, Clifford B, Zeft AS, et al. Elevated serum levels of soluble CD154 in children with juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2008;6:8.PubMedCrossRefPubMedCentral
19.
go back to reference Tamura N, Kobayashi S, Kato K, Bando H, Haruta K, Oyanagi M, et al. Soluble CD154 in rheumatoid arthritis: elevated plasma levels in cases with vasculitis. J Rheumatol. 2001;28:2583–90.PubMed Tamura N, Kobayashi S, Kato K, Bando H, Haruta K, Oyanagi M, et al. Soluble CD154 in rheumatoid arthritis: elevated plasma levels in cases with vasculitis. J Rheumatol. 2001;28:2583–90.PubMed
20.
go back to reference Chung WS, Peng CL, Lin CL, Chang YJ, Chen YF, Chiang JY, et al. Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study. Ann Rheum Dis. 2014;73:1774–80.PubMedCrossRef Chung WS, Peng CL, Lin CL, Chang YJ, Chen YF, Chiang JY, et al. Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study. Ann Rheum Dis. 2014;73:1774–80.PubMedCrossRef
21.
go back to reference Holmqvist ME, Neovius M, Eriksson J, Mantel Ä, Wållberg-Jonsson S, Jacobsson LT, et al. Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization. JAMA. 2012;308:1350–6.PubMedCrossRef Holmqvist ME, Neovius M, Eriksson J, Mantel Ä, Wållberg-Jonsson S, Jacobsson LT, et al. Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization. JAMA. 2012;308:1350–6.PubMedCrossRef
22.
go back to reference Gustafsson JT, Simard JF, Gunnarsson I, Elvin K, Lundberg IE, Hansson LO, et al. Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study. Arthritis Res Ther. 2012;14:R46.PubMedCrossRefPubMedCentral Gustafsson JT, Simard JF, Gunnarsson I, Elvin K, Lundberg IE, Hansson LO, et al. Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study. Arthritis Res Ther. 2012;14:R46.PubMedCrossRefPubMedCentral
23.
go back to reference Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med. 2007;146:797–808.PubMedCrossRef Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med. 2007;146:797–808.PubMedCrossRef
24.
go back to reference van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther. 2005;7:R949–58.CrossRef van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther. 2005;7:R949–58.CrossRef
25.
go back to reference van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum. 2004;50:709–15.PubMedCrossRef van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum. 2004;50:709–15.PubMedCrossRef
26.
go back to reference Cambridge G, Acharya J, Cooper JA, Edwards JC, Humphries SE. Antibodies to citrullinated peptides and risk of coronary heart disease. Atherosclerosis. 2013;228:243–6.PubMedCrossRef Cambridge G, Acharya J, Cooper JA, Edwards JC, Humphries SE. Antibodies to citrullinated peptides and risk of coronary heart disease. Atherosclerosis. 2013;228:243–6.PubMedCrossRef
27.
go back to reference El-Barbary AM, Kassem EM, El-Sergany MA, Essa SA, Eltomey MA. Association of anti-modified citrullinated vimentin with subclinical atherosclerosis in early rheumatoid arthritis compared with anti-cyclic citrullinated peptide. J Rheumatol. 2011;38:828–34.PubMedCrossRef El-Barbary AM, Kassem EM, El-Sergany MA, Essa SA, Eltomey MA. Association of anti-modified citrullinated vimentin with subclinical atherosclerosis in early rheumatoid arthritis compared with anti-cyclic citrullinated peptide. J Rheumatol. 2011;38:828–34.PubMedCrossRef
28.
go back to reference Gerli R, Bartoloni Bocci E, Sherer Y, Vaudo G, Moscatelli S, Shoenfeld Y. Association of anti-cyclic citrullinated peptide antibodies with subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67:724–5.PubMedCrossRef Gerli R, Bartoloni Bocci E, Sherer Y, Vaudo G, Moscatelli S, Shoenfeld Y. Association of anti-cyclic citrullinated peptide antibodies with subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67:724–5.PubMedCrossRef
29.
go back to reference Giles JT, Fert-Bober J, Park JK, Bingham 3rd CO, Andrade F, Fox-Talbot K, et al. Myocardial citrullination in rheumatoid arthritis: a correlative histopathologic study. Arthritis Res Ther. 2012;14:R39.PubMedCrossRefPubMedCentral Giles JT, Fert-Bober J, Park JK, Bingham 3rd CO, Andrade F, Fox-Talbot K, et al. Myocardial citrullination in rheumatoid arthritis: a correlative histopathologic study. Arthritis Res Ther. 2012;14:R39.PubMedCrossRefPubMedCentral
30.
go back to reference Goodson NJ, Wiles NJ, Lunt M, Barrett EM, Silman AJ, Symmons DP. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum. 2002;46:2010–9.PubMedCrossRef Goodson NJ, Wiles NJ, Lunt M, Barrett EM, Silman AJ, Symmons DP. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum. 2002;46:2010–9.PubMedCrossRef
31.
go back to reference Hjeltnes G, Hollan I, Forre O, Wiik A, Mikkelsen K, Agewall S. Anti-CCP and RF IgM: predictors of impaired endothelial function in rheumatoid arthritis patients. Scand J Rheumatol. 2011;40:422–7.PubMedCrossRef Hjeltnes G, Hollan I, Forre O, Wiik A, Mikkelsen K, Agewall S. Anti-CCP and RF IgM: predictors of impaired endothelial function in rheumatoid arthritis patients. Scand J Rheumatol. 2011;40:422–7.PubMedCrossRef
32.
go back to reference López-Longo FJ, Oliver-Miñarro D, de la Torre I, González-Díaz de Rábago E, Sánchez-Ramón S, Rodríguez-Mahou M, et al. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum. 2009;61:419–24.PubMedCrossRef López-Longo FJ, Oliver-Miñarro D, de la Torre I, González-Díaz de Rábago E, Sánchez-Ramón S, Rodríguez-Mahou M, et al. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum. 2009;61:419–24.PubMedCrossRef
33.
go back to reference Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2005;52:722–32.PubMedCrossRef Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2005;52:722–32.PubMedCrossRef
34.
go back to reference Tomasson G, Aspelund T, Jonsson T, Valdimarsson H, Felson DT, Gudnason V. Effect of rheumatoid factor on mortality and coronary heart disease. Ann Rheum Dis. 2010;69:1649–54.PubMedCrossRefPubMedCentral Tomasson G, Aspelund T, Jonsson T, Valdimarsson H, Felson DT, Gudnason V. Effect of rheumatoid factor on mortality and coronary heart disease. Ann Rheum Dis. 2010;69:1649–54.PubMedCrossRefPubMedCentral
35.
go back to reference Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.PubMedCrossRef Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.PubMedCrossRef
36.
go back to reference Vergeer M, Korporaal SJ, Franssen R, Meurs I, Out R, Hovingh GK, et al. Genetic variant of the scavenger receptor BI in humans. N Engl J Med. 2011;364:136–45.PubMedCrossRef Vergeer M, Korporaal SJ, Franssen R, Meurs I, Out R, Hovingh GK, et al. Genetic variant of the scavenger receptor BI in humans. N Engl J Med. 2011;364:136–45.PubMedCrossRef
37.
go back to reference Matzdorff AC, Kühnel G, Kemkes-Matthes B, Pralle H. Quantitative assessment of platelets, platelet microparticles, and platelet aggregates with flow cytometry. J Lab Clin Med. 1998;131:507–17.PubMedCrossRef Matzdorff AC, Kühnel G, Kemkes-Matthes B, Pralle H. Quantitative assessment of platelets, platelet microparticles, and platelet aggregates with flow cytometry. J Lab Clin Med. 1998;131:507–17.PubMedCrossRef
38.
go back to reference Pignatelli P, De Biase L, Lenti L, Tocci G, Brunelli A, Cangemi R, et al. Tumor necrosis factor-α as trigger of platelet activation in patients with heart failure. Blood. 2005;106:1992–4.PubMedCrossRef Pignatelli P, De Biase L, Lenti L, Tocci G, Brunelli A, Cangemi R, et al. Tumor necrosis factor-α as trigger of platelet activation in patients with heart failure. Blood. 2005;106:1992–4.PubMedCrossRef
39.
go back to reference Boilard E, Larabee K, Shnayder R, Jacobs K, Farndale RW, Ware J, et al. Platelets participate in synovitis via Cox-1-dependent synthesis of prostacyclin independently of microparticle generation. J Immunol. 2011;186:4361–6.PubMedCrossRefPubMedCentral Boilard E, Larabee K, Shnayder R, Jacobs K, Farndale RW, Ware J, et al. Platelets participate in synovitis via Cox-1-dependent synthesis of prostacyclin independently of microparticle generation. J Immunol. 2011;186:4361–6.PubMedCrossRefPubMedCentral
40.
go back to reference Schmitt-Sody M, Klose A, Gottschalk O, Metz P, Gebhard H, Zysk S, et al. Platelet-endothelial cell interactions in murine antigen-induced arthritis. Rheumatology (Oxford). 2005;44:885–9.CrossRef Schmitt-Sody M, Klose A, Gottschalk O, Metz P, Gebhard H, Zysk S, et al. Platelet-endothelial cell interactions in murine antigen-induced arthritis. Rheumatology (Oxford). 2005;44:885–9.CrossRef
41.
go back to reference Schmitt-Sody M, Metz P, Gottschalk O, Birkenmaier C, Zysk S, Veihelmann A, et al. Platelet P-selectin is significantly involved in leukocyte-endothelial cell interaction in murine antigen-induced arthritis. Platelets. 2007;18:365–72.PubMedCrossRef Schmitt-Sody M, Metz P, Gottschalk O, Birkenmaier C, Zysk S, Veihelmann A, et al. Platelet P-selectin is significantly involved in leukocyte-endothelial cell interaction in murine antigen-induced arthritis. Platelets. 2007;18:365–72.PubMedCrossRef
42.
go back to reference Wang F, Wang NS, Yan CG, Li JH, Tang LQ. The significance of platelet activation in rheumatoid arthritis. Clin Rheumatol. 2007;26:768–71.PubMedCrossRef Wang F, Wang NS, Yan CG, Li JH, Tang LQ. The significance of platelet activation in rheumatoid arthritis. Clin Rheumatol. 2007;26:768–71.PubMedCrossRef
43.
go back to reference Demirin H, Ozhan H, Ucgun T, Celer A, Bulur S, Cil H, et al. Normal range of mean platelet volume in healthy subjects: Insight from a large epidemiologic study. Thromb Res. 2011;128:358–60.PubMedCrossRef Demirin H, Ozhan H, Ucgun T, Celer A, Bulur S, Cil H, et al. Normal range of mean platelet volume in healthy subjects: Insight from a large epidemiologic study. Thromb Res. 2011;128:358–60.PubMedCrossRef
44.
go back to reference Lippi G, Meschi T, Borghi L. Mean platelet volume increases with aging in a large population study. Thromb Res. 2012;129:e159–60.PubMedCrossRef Lippi G, Meschi T, Borghi L. Mean platelet volume increases with aging in a large population study. Thromb Res. 2012;129:e159–60.PubMedCrossRef
45.
go back to reference Yazici S, Yazici M, Erer B, Calik Y, Ozhan H, Ataoglu S. The platelet indices in patients with rheumatoid arthritis: mean platelet volume reflects disease activity. Platelets. 2010;21:122–5.PubMedCrossRef Yazici S, Yazici M, Erer B, Calik Y, Ozhan H, Ataoglu S. The platelet indices in patients with rheumatoid arthritis: mean platelet volume reflects disease activity. Platelets. 2010;21:122–5.PubMedCrossRef
46.
go back to reference Beinsberger J, Heemskerk JW, Cosemans JM. Chronic arthritis and cardiovascular disease: altered blood parameters give rise to a prothrombotic propensity. Semin Arthritis Rheum. 2014;44:345–52.PubMedCrossRef Beinsberger J, Heemskerk JW, Cosemans JM. Chronic arthritis and cardiovascular disease: altered blood parameters give rise to a prothrombotic propensity. Semin Arthritis Rheum. 2014;44:345–52.PubMedCrossRef
47.
go back to reference Espinola RG, Pierangeli SS, Gharavi AE, Harris EN. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost. 2002;87:518–22.PubMed Espinola RG, Pierangeli SS, Gharavi AE, Harris EN. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost. 2002;87:518–22.PubMed
48.
go back to reference Yazici S, Yazici M, Erer B, Calik Y, Bulur S, Ozhan H, et al. The platelet functions in patients with ankylosing spondylitis: anti-TNF-α therapy decreases the mean platelet volume and platelet mass. Platelets. 2010;21:126–31.PubMedCrossRef Yazici S, Yazici M, Erer B, Calik Y, Bulur S, Ozhan H, et al. The platelet functions in patients with ankylosing spondylitis: anti-TNF-α therapy decreases the mean platelet volume and platelet mass. Platelets. 2010;21:126–31.PubMedCrossRef
49.
go back to reference Miguélez R, Palacios I, Navarro F, Gutierrez S, Sanchez-Pernaute O, Egido J, et al. Anti-inflammatory effect of a PAF receptor antagonist and a new molecule with antiproteinase activity in an experimental model of acute urate crystal arthritis. J Lipid Mediat Cell Signal. 1996;13:35–49.PubMedCrossRef Miguélez R, Palacios I, Navarro F, Gutierrez S, Sanchez-Pernaute O, Egido J, et al. Anti-inflammatory effect of a PAF receptor antagonist and a new molecule with antiproteinase activity in an experimental model of acute urate crystal arthritis. J Lipid Mediat Cell Signal. 1996;13:35–49.PubMedCrossRef
50.
go back to reference Pignatelli P, Cangemi R, Celestini A, Carnevale R, Polimeni L, Martini A, et al. Tumour necrosis factor α upregulates platelet CD40L in patients with heart failure. Cardiovasc Res. 2008;78:515–22.PubMedCrossRef Pignatelli P, Cangemi R, Celestini A, Carnevale R, Polimeni L, Martini A, et al. Tumour necrosis factor α upregulates platelet CD40L in patients with heart failure. Cardiovasc Res. 2008;78:515–22.PubMedCrossRef
51.
go back to reference King M, McDermott P, Schreiber AD. Characterization of the Fcγ receptor on human platelets. Cell Immunol. 1990;128:462–79.PubMedCrossRef King M, McDermott P, Schreiber AD. Characterization of the Fcγ receptor on human platelets. Cell Immunol. 1990;128:462–79.PubMedCrossRef
52.
go back to reference Falus A, Merétey K, Bagdy D, Diószegi M, Böhm U, Csák E, et al. β-2-microglobulin-specific autoantibodies cause platelet aggregation and interfere with ADP-induced aggregation. Clin Exp Immunol. 1982;47:103–9.PubMedPubMedCentral Falus A, Merétey K, Bagdy D, Diószegi M, Böhm U, Csák E, et al. β-2-microglobulin-specific autoantibodies cause platelet aggregation and interfere with ADP-induced aggregation. Clin Exp Immunol. 1982;47:103–9.PubMedPubMedCentral
53.
go back to reference Fink PC, Piening U, Fricke PM, Deicher H. Platelet aggregation and aggregation inhibition by different antiglobulins and antiglobulin complexes from sera of patients with rheumatoid arthritis. Arthritis Rheum. 1979;22:896–903.PubMedCrossRef Fink PC, Piening U, Fricke PM, Deicher H. Platelet aggregation and aggregation inhibition by different antiglobulins and antiglobulin complexes from sera of patients with rheumatoid arthritis. Arthritis Rheum. 1979;22:896–903.PubMedCrossRef
54.
go back to reference Duffau P, Seneschal J, Nicco C, Richez C, Lazaro E, Douchet I, et al. Platelet CD154 potentiates interferon-α secretion by plasmacytoid dendritic cells in systemic lupus erythematosus. Sci Transl Med. 2010;2:47ra63.PubMedCrossRef Duffau P, Seneschal J, Nicco C, Richez C, Lazaro E, Douchet I, et al. Platelet CD154 potentiates interferon-α secretion by plasmacytoid dendritic cells in systemic lupus erythematosus. Sci Transl Med. 2010;2:47ra63.PubMedCrossRef
55.
go back to reference Berlacher MD, Vieth JA, Heflin BC, Gay SR, Antczak AJ, Tasma BE, et al. FcγRIIa ligation induces platelet hypersensitivity to thrombotic stimuli. Am J Pathol. 2013;182:244–54.PubMedCrossRef Berlacher MD, Vieth JA, Heflin BC, Gay SR, Antczak AJ, Tasma BE, et al. FcγRIIa ligation induces platelet hypersensitivity to thrombotic stimuli. Am J Pathol. 2013;182:244–54.PubMedCrossRef
56.
go back to reference Kubagawa H, Oka S, Kubagawa Y, Torii I, Takayama E, Kang DW, et al. Identity of the elusive IgM Fc receptor (FcμR) in humans. J Exp Med. 2009;206:2779–93.PubMedCrossRefPubMedCentral Kubagawa H, Oka S, Kubagawa Y, Torii I, Takayama E, Kang DW, et al. Identity of the elusive IgM Fc receptor (FcμR) in humans. J Exp Med. 2009;206:2779–93.PubMedCrossRefPubMedCentral
57.
go back to reference Scott DG, Bacon PA, Allen C, Elson CJ, Wallington T. IgG rheumatoid factor, complement and immune complexes in rheumatoid synovitis and vasculitis: comparative and serial studies during cytotoxic therapy. Clin Exp Immunol. 1981;43:54–63.PubMedPubMedCentral Scott DG, Bacon PA, Allen C, Elson CJ, Wallington T. IgG rheumatoid factor, complement and immune complexes in rheumatoid synovitis and vasculitis: comparative and serial studies during cytotoxic therapy. Clin Exp Immunol. 1981;43:54–63.PubMedPubMedCentral
58.
go back to reference Wipke BT, Wang Z, Kim J, McCarthy TJ, Allen PM. Dynamic visualization of a joint-specific autoimmune response through positron emission tomography. Nat Immunol. 2002;3:366–72.PubMedCrossRef Wipke BT, Wang Z, Kim J, McCarthy TJ, Allen PM. Dynamic visualization of a joint-specific autoimmune response through positron emission tomography. Nat Immunol. 2002;3:366–72.PubMedCrossRef
59.
go back to reference Matsumoto I, Maccioni M, Lee DM, Maurice M, Simmons B, Brenner M, et al. How antibodies to a ubiquitous cytoplasmic enzyme may provoke joint-specific autoimmune disease. Nat Immunol. 2002;3:360–5.PubMedCrossRef Matsumoto I, Maccioni M, Lee DM, Maurice M, Simmons B, Brenner M, et al. How antibodies to a ubiquitous cytoplasmic enzyme may provoke joint-specific autoimmune disease. Nat Immunol. 2002;3:360–5.PubMedCrossRef
Metadata
Title
Anti-citrullinated protein antibodies contribute to platelet activation in rheumatoid arthritis
Authors
Kim L.L. Habets
Leendert A. Trouw
E.W. Nivine Levarht
Suzanne J.A. Korporaal
Petra A.M. Habets
Philip de Groot
Tom W.J. Huizinga
René E.M. Toes
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2015
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/s13075-015-0665-7

Other articles of this Issue 1/2015

Arthritis Research & Therapy 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.